• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Ignyte Acquisition Corp.

    2/6/24 4:09:01 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials
    Get the next $IGNY alert in real time by email
    8-K
    NONE 0001834645 false 0001834645 2024-01-05 2024-01-05

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(D)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported): January 5, 2024

     

     

    Peak Bio, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-39951   85-2448157

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    4900 Hopyard Road, Suite 100
    Pleasanton, CA 94588
    (Address of principal executive offices, including zip code)

    (925) 463-4800

    (Registrant’s telephone number, including area code)

    (Former name or former address, if changed since last report)

     

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbols

     

    Name of each exchange

    on which registered

    Common stock, par value $0.0001 per share   PKBO   OTCQB

    Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      ☐

    Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ☐

    Pre-commencements communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 3.02 Unregistered Sales of Equity Securities.

    As previously disclosed by Peak Bio, Inc., a Delaware corporation (the “Company”), on its Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on December 22, 2023 (the “December 22, 2023 Current Report”) the Company and certain investors (the “Convertible Note Investors”) entered into a convertible note subscription agreement dated December 18, 2023 (the “Convertible Note Subscription Agreement”) pursuant to which (i) the Convertible Note Investors purchased and the Company issued to the Convertible Note Investors convertible promissory notes (the “Convertible Notes”) in the aggregate principal amount of $1,000,000 and (ii) certain convertible notes previously issued by the Company on or about April 28, 2023 in the aggregate original principal amount of $180,000 were exchanged for new Convertible Notes.

    As previously disclosed on the Company’s Current Report on Form 8-K filed with the SEC on January 3, 2024, the Company closed a second financing under the Convertible Note Subscription Agreement with a Convertible Note Investor pursuant to which a Convertible Note Investor purchased and the Company issued to the Convertible Note Investor Convertible Notes in the aggregate principal amount of $500,000.

    On January 31, 2024, the Company closed an additional financing under the Convertible Note Subscription Agreement with Convertible Note Investors pursuant to which (i) Convertible Note Investors purchased and the Company issued to the Convertible Note Investors Convertible Notes in the aggregate principal amount of $675,000 and (ii) certain convertible notes previously issued by the Company on or about April 28, 2023 in the aggregate original principal amount of $240,000 were exchanged for new Convertible Notes.

    The Convertible Notes carry an interest rate of 10% per annum, have a maturity date occurring on the 12-month anniversary date of the initial closing date of December 18, 2023 (the “Initial Closing Date”), and provide for automatic conversion, optional conversion and registration rights as follows:

    Automatic Conversion:

    If a Business Combination (defined below) occurs while the Convertible Notes are outstanding, then the outstanding principal amount of the Convertible Notes and all accrued and unpaid interest shall automatically convert into common stock, par value $0.0001 per share (the “Common Stock”) of the Company immediately prior to the closing of the Business Combination at the Conversion Price (defined below) where:

    “Business Combination” means any reorganization, recapitalization, reclassification, consolidation or merger involving the Company in which the Common Stock of the Company is converted into or exchanged for securities of another entity (the “Surviving Company”) that are traded on a Public Exchange (the “Surviving Company Securities”).

    “Conversion Price” means the price per share for the Company’s Common Stock determined by reference to the purchase price payable in connection with such Business Combination, multiplied by the Discount Rate, where the price per share of the Common Stock is determined by reference to the 30-day volume weighted average price of the Surviving Company Securities on the Public Exchange immediately prior to conversion and the exchange ratio (the “Exchange Ratio”) used in the Business Combination.

    “Discount Rate” means 70%.

    “Public Exchange” means the Nasdaq Stock Market, the New York Stock Exchange or another public exchange or marketplace approved by the Company’s Board of Directors.

    Optional Conversion:

    If a Business Combination does not occur prior to the maturity date of the Convertible Notes and if the Company’s Common Stock is listed on a Public Exchange as of such date, then the Convertible Note Investors will have the right, at their option, to convert the outstanding principal amount of the Convertible Notes (and all accrued and unpaid interest thereof) into fully paid and nonassessable shares of Common Stock of the Company at a price equal to the 30-day volume weighted average price of the Company’s Common Stock on the Public Exchange on which it is traded multiplied by 90%.


    Registration Rights:

    Upon the Company’s next equity financing after the Initial Closing Date (the “Next Financing”) in which the Company provides future investors with registration rights, the Company will provide substantially equivalent registration rights to the Convertible Note Investors with respect to the shares of Common Stock into which the Convertible Notes are convertible, subject to the Convertible Notes Investors’ execution of any documents executed by the investors purchasing securities in the Next Financing.

    The foregoing descriptions of the Convertible Note Subscription Agreement and Convertible Notes are qualified in their entirety by reference to the full text of the form of Convertible Note Subscription Agreement and form of Convertible Note, which were attached as Exhibits to the December 22, 2023 Current Report and are incorporated herein by reference.

     


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Dated: February 6, 2024

     

    PEAK BIO, INC.
    By:  

    /s/ Stephen LaMond

    Name:   Stephen LaMond
    Title:   Interim Chief Executive Officer
    Get the next $IGNY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IGNY

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IGNY
    SEC Filings

    View All

    SEC Form 8-K filed by Ignyte Acquisition Corp.

    8-K - Peak Bio, Inc. (0001834645) (Filer)

    2/6/24 4:09:01 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    SEC Form 8-K filed by Ignyte Acquisition Corp.

    8-K - Peak Bio, Inc. (0001834645) (Filer)

    1/29/24 5:08:05 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    Ignyte Acquisition Corp. filed SEC Form 8-K: Unregistered Sales of Equity Securities

    8-K - Peak Bio, Inc. (0001834645) (Filer)

    1/3/24 5:08:00 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    $IGNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lamond Stephen J bought 5,600 shares, increasing direct ownership by 39% to 19,850 units (SEC Form 4)

    4 - Peak Bio, Inc. (0001834645) (Issuer)

    9/28/23 4:05:23 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    Lamond Stephen J bought 14,250 shares (SEC Form 4) (Amendment)

    4/A - Peak Bio, Inc. (0001834645) (Issuer)

    9/28/23 4:05:04 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    SEC Form 4: Huh Hoyoung bought 45,000 shares, increasing direct ownership by 0.54% to 8,382,742 units

    4 - Peak Bio, Inc. (0001834645) (Issuer)

    9/25/23 4:05:03 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    $IGNY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Peak Bio Co., Ltd. to List on NASDAQ Following Successful Business Combination with Ignyte Acquisition Corp.

    Combined Company Scheduled to Commence Trading on NASDAQ Under the Ticker Symbol "PKBO" Peak Bio Co., Ltd. ("Peak Bio"), a clinical-stage biopharmaceutical company focused on developing the next-generation of therapeutics to treat oncology and inflammatory diseases, today announced the completion of its business combination (the "Business Combination") with Ignyte Acquisition Corp. (NASDAQ:IGNY) ("Ignyte"), a special purpose acquisition company. The transaction was approved at a special meeting of Ignyte's stockholders held on October 25, 2022 (the "Special Meeting"). Ignyte's stockholders also voted to approve all other proposals presented at the Special Meeting. Ignyte's Board of Direct

    11/2/22 7:30:00 AM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    Ignyte Acquisition Corp. Stockholders Approve Proposed Business Combination with Peak Bio

    Transaction Expected to Close on October 31, 2022 Ignyte Acquisition Corp. ("Ignyte") (NASDAQ:IGNY), a publicly traded special purpose acquisition company, today announced that Ignyte's stockholders have approved its proposed business combination (the "Business Combination") with Peak Bio Co., Ltd. ("Peak Bio") at a Special Meeting of its stockholders held on October 25, 2022 (the "Special Meeting"). The Special Meeting to be held on October 31, 2022 has been canceled. Approximately 75% of the votes cast at the Special Meeting, representing approximately 75% of Ignyte's outstanding shares of common stock entitled to vote at the Special Meeting, were cast in favor of the proposal to approv

    10/27/22 8:05:00 AM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    Peak Bio and Ignyte Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Oncology and Inflammation Company

    - Company to be led by Hoyoung Huh, M.D. Ph.D., serial entrepreneur / investor with notable public and private biotech board positions - $25 million private investment in public equity ("PIPE") with participation from leading healthcare institutional investor, Palo Alto Investors (PAI) with additional participation from Peak Bio's CEO, Hoyoung Huh, MD, Ph.D. - Differentiated pipeline includes next generation Neutrophil Elastase Inhibitor targeting AATD / ARDS and robust preclinical ADC oncology platform utilizing Antibody Drug Conjugates - Anticipated cash at closing expected to fully fund the company through 2024 allowing for multiple milestones in ADC program and interim Phase II for A

    4/28/22 4:32:00 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    $IGNY
    Financials

    Live finance-specific insights

    View All

    Peak Bio and Ignyte Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Oncology and Inflammation Company

    - Company to be led by Hoyoung Huh, M.D. Ph.D., serial entrepreneur / investor with notable public and private biotech board positions - $25 million private investment in public equity ("PIPE") with participation from leading healthcare institutional investor, Palo Alto Investors (PAI) with additional participation from Peak Bio's CEO, Hoyoung Huh, MD, Ph.D. - Differentiated pipeline includes next generation Neutrophil Elastase Inhibitor targeting AATD / ARDS and robust preclinical ADC oncology platform utilizing Antibody Drug Conjugates - Anticipated cash at closing expected to fully fund the company through 2024 allowing for multiple milestones in ADC program and interim Phase II for A

    4/28/22 4:32:00 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    $IGNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lamond Stephen J bought 5,600 shares, increasing direct ownership by 39% to 19,850 units (SEC Form 4)

    4 - Peak Bio, Inc. (0001834645) (Issuer)

    9/28/23 4:05:23 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    Lamond Stephen J bought 14,250 shares (SEC Form 4) (Amendment)

    4/A - Peak Bio, Inc. (0001834645) (Issuer)

    9/28/23 4:05:04 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    SEC Form 4: Huh Hoyoung bought 45,000 shares, increasing direct ownership by 0.54% to 8,382,742 units

    4 - Peak Bio, Inc. (0001834645) (Issuer)

    9/25/23 4:05:03 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    $IGNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Ignyte Acquisition Corp.

    SC 13D - Peak Bio, Inc. (0001834645) (Subject)

    3/21/23 5:30:30 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13G filed by Ignyte Acquisition Corp.

    SC 13G - Peak Bio, Inc. (0001834645) (Subject)

    2/28/23 4:01:06 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13G/A filed by Ignyte Acquisition Corp. (Amendment)

    SC 13G/A - Peak Bio, Inc. (0001834645) (Subject)

    2/14/23 3:39:04 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials